Invention Grant
- Patent Title: Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
-
Application No.: US15284334Application Date: 2016-10-03
-
Publication No.: US09908868B2Publication Date: 2018-03-06
- Inventor: Lothar Schwink , Christian Buning , Heiner Glombik , Matthias Gossel , Dieter Kadereit , Nis Halland , Matthias Lohmann , Christoph Pöverlein , Kurt Ritter
- Applicant: SANOFI
- Applicant Address: FR Paris
- Assignee: SANOFI
- Current Assignee: SANOFI
- Current Assignee Address: FR Paris
- Agency: Morrison & Foerster LLP
- Priority: EP14305496 20140404
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D413/14 ; C07D403/04 ; C07D417/14 ; A61K31/155 ; A61K31/397 ; A61K31/40 ; A61K31/4035 ; A61K31/437 ; A61K31/4439 ; A61K31/444 ; A61K31/4545 ; A61K31/517 ; A61K31/702 ; A61K45/06 ; C07D405/14 ; C07D471/04
Abstract:
The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
Public/Granted literature
Information query
